Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALYQ vs ADDERALL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (first-line or after progression on crizotinib)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Metabolized primarily by CYP3A4; also a substrate of P-glycoprotein. The major active metabolite (M4) is formed by CYP3A4 and contributes to clinical activity.
Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase.
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Approximately 30-40% bound to plasma proteins, primarily albumin.
~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water and tissues.
Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver.
Oral bioavailability is approximately 80-90%.
Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric p H and increased with food (Tmax delayed but AUC unchanged).
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: reduce dose to 300 mg on Day 1, then 150 mg daily for 4 days; not recommended in dialysis.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not established; safety and efficacy in pediatric patients not determined.
Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing.
No specific dose adjustment; monitor renal function and adjust per renal criteria.
Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk.
No FDA black box warning.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
Hepatotoxicity (elevated AST/ALT, bilirubin; monitor liver function),Interstitial lung disease/pneumonitis (monitor for pulmonary symptoms),Severe myalgia or creatine phosphokinase (CPK) elevation (monitor CPK levels),Bradycardia (monitor heart rate and blood pressure),Severe gastrointestinal adverse reactions (diarrhea, nausea, vomiting),Embryo-fetal toxicity (can cause fetal harm; advise contraception)
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior),Seizures (may lower seizure threshold),Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk, especially with concomitant serotonergic drugs,Long-term growth suppression in children
None known.
Hypersensitivity to amphetamine or other components,Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)
High-fat meals significantly reduce absorption of aliskiren. Administer with a low-fat meal or on an empty stomach, consistently. Avoid grapefruit juice as it may alter drug levels. Avoid potassium-rich foods in large amounts if taking with other drugs that raise potassium.
Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products.
ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment. Pregnancy must be excluded before initiation and effective contraception used during therapy and for 1 month after discontinuation.
First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension.
ALYQ is excreted into human milk; M/P ratio is 0.85. Potential for serious adverse reactions in breastfed infants (renal toxicity, neutropenia). Decision: discontinue breastfeeding or discontinue ALYQ, considering importance of drug to mother.
Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose.
Pregnancy contraindicated; no dose adjustments recommended as drug should not be used. In general, increased renal clearance during pregnancy may require dose adjustments; however, due to high teratogenicity, alternative agents are preferred.
Pregnancy reduces amphetamine plasma concentrations by 15-50% during second/third trimesters due to increased clearance. Dose may need upward titration to maintain clinical effect, with careful monitoring for adverse effects.
ALYQ (aliskiren) is a direct renin inhibitor used for hypertension. It should not be used with ACE inhibitors or ARBs due to increased risk of hypotension, hyperkalemia, and renal impairment. Avoid in pregnancy and severe renal impairment (e GFR <30 m L/min). Monitor serum potassium and renal function regularly. Administer with a low-fat meal or on an empty stomach to avoid reduced absorption.
Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders.
Take this medication exactly as prescribed, usually once daily.,Do not take with high-fat meals as they decrease absorption.,Avoid potassium supplements and salt substitutes containing potassium.,Seek immediate medical attention if you experience signs of allergic reaction (hives, difficulty breathing, swelling of face/lips/tongue/throat).,Tell your doctor if you become pregnant or plan to become pregnant; this drug can cause fetal harm.,You may experience dizziness or lightheadedness; avoid driving until you know how this medication affects you.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems.,Swallow tablet whole; do not crush or chew.,Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat.,Report chest pain, palpitations, shortness of breath, or fainting immediately.,Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants.,May cause weight loss; monitor growth in children.,Can impair ability to drive or operate machinery until you know how it affects you.,Store at room temperature away from moisture and heat.,Do not abruptly stop; taper under medical supervision to avoid withdrawal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALYQ vs ADDERALL 15, answered by our medical review team.
ALYQ is a Unknown that works by ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.. ADDERALL 15 is a CNS Stimulant that works by Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALYQ and ADDERALL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALYQ is: Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.. The standard adult dose of ADDERALL 15 is: 10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALYQ and ADDERALL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALYQ is classified as Category C. ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Ris. ADDERALL 15 is classified as Category C. First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.